Publication: Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
Loading...
Program
relationships.isAuthorOf
Author
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
Keywords
Keywords
Citation
Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021